Oxford Asset Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Oxford Asset Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-28,380	Closed	-$15K	–	1718
2019 Q4	$15K	Buy	+28,380	New	+$68.8K	﹤0.01%	1699
2019 Q1	–	Sell	-35,643	Closed	-$141K	–	2169
2018 Q4	$141K	Buy	+35,643	New	+$456K	﹤0.01%	1608
2018 Q3	–	Sell	-18,903	Closed	-$599K	–	2064
2018 Q2	$599K	Buy	18,903 +14,407	+320%	+$519K	0.01%	1271
2018 Q1	$166K	Buy	+4,496	New	+$296K	﹤0.01%	1503

Oxford Asset Management's MLNT Position: Q1 2020 in Review

Oxford Asset Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 28,380 shares — an estimated $15K sold.

Oxford Asset Management first reported a position in MLNT in Q1 2018 and held it in 4 quarters. The position peaked at $599K in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Oxford Asset Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 28,380 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $15K.
Oxford Asset Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 4 quarters.
Oxford Asset Management's Melinta Therapeutics, Inc. Common Stock position peaked at $599K in Q2 2018.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.